Neurology companies develop therapies, diagnostics and technologies that improve understanding and treatment of disorders affecting the brain, spinal cord and nervous system. The field addresses some of the most complex challenges in modern medicine.
This category includes companies working on:
Browse 114 UK neurology companies below.
Natural product-inspired small molecules for sexual and mental health
Kadence Bio is a clinical-stage biopharma company developing small molecule therapeutics for sexual and mental health. Its lead asset KH-001 is an on-demand oral treatment for premature ejaculation, developed from nature-inspired medicinal chemistry based on kanna plant alkaloids and optimised through standard drug…
Human iPSC platform for neurodegenerative disease drug discovery
Talisman Therapeutics is a drug discovery company specialising in human induced pluripotent stem cell (iPSC) models of neurodegenerative disease. The company operates both an internal discovery pipeline, focused on Alzheimer's disease targets including lysosome biology, pathogenic protein reduction and microglial…
Investigational oral ketamine formulations for treatment-resistant depression
Neurocentrx Pharma is a clinical-stage biopharmaceutical company developing oral ketamine formulations for treatment-resistant mood disorders. Its NRCx-201 programme includes immediate-release and abuse-deterrent capsules intended for clinically supervised treatment and potentially supported home care. Following…
Clinical-stage CNS drug discovery using human brain genomics
Cerevance is a clinical-stage biotechnology company developing small molecule therapeutics for neurodegenerative and psychiatric disorders. The company uses its proprietary platform to profile gene expression in specific neuronal and glial cell types from a collection of over 16,000 annotated human brain tissue…
Patient-derived mitochondrial screening for preclinical drug discovery
Mitotype Precision Labs is a contract research organisation providing patient-derived cellular assays for drug discovery and preclinical evaluation. Its screening services use fibroblasts, neurons and astrocytes to measure mitochondrial function, lysosomal biology and other disease-relevant cellular responses. The…
Curative genetic medicines for peripheral nerve diseases
CureAge Therapeutics develops genetic medicines for peripheral nerve disorders, initially targeting neurofibromatosis type 1 (NF1). Its investigational platform uses locally delivered lipid nanoparticles to carry genetic material into Schwann cells, aiming to restore NF1 gene function and address surrounding tumour…
UK affiliate of global family-owned biopharmaceutical company
Boehringer Ingelheim is a global family-owned biopharmaceutical company founded in 1885. Its Bracknell headquarters houses functions spanning research and development, regulatory affairs, pharmacovigilance, medical affairs, and commercial operations across its human pharma and animal health divisions. It operates…
Antibody discovery platform identifying therapeutics from resilient individuals
Alchemab Therapeutics is a clinical-stage biopharmaceutical company developing antibody therapeutics for neurodegenerative diseases, oncology, and immunology. Its platform combines deep B cell sequencing and machine learning to identify naturally protective antibodies from individuals resilient to specific diseases.…
Full-service CRO delivering UK clinical trials across dedicated research sites
MAC Clinical Research is a contract research organisation conducting Phase I to IV clinical trials for pharmaceutical and biotechnology sponsors. The company operates a fully owned network of dedicated research sites across the UK, including an MHRA accredited Phase I unit, backed by international offices. Services…
Clinical trial delivery for Alzheimer's and neurodegenerative disease
Scottish Brain Sciences is a contract research organisation building and operating clinical trial infrastructure for Alzheimer's disease and other neurodegenerative conditions. Working with pharmaceutical sponsors, it delivers trial screening, patient recruitment, and study conduct at dedicated clinical sites in…
Real-world mental health and dementia data platform for drug development
Akrivia Health is a software company providing a real-world data and AI platform for neuroscience research and drug development. Its dataset of de-identified electronic health records from 6.3 million patients across 20 NHS Trusts covers mental health and dementia conditions, enriched through proprietary natural…
Novel small-molecule therapeutics for neurodegenerative diseases
Nevrargenics is a UK-based biotech company developing novel small-molecule therapeutics for neurodegenerative diseases. Spun out of Durham University and built on research collaboration with the University of Aberdeen, the company uses a patented library of dual-activity retinoic acid receptor modulators designed to…
Micellar oral cannabidiol formulation for psychiatric drug development
NWPharmaTech is a clinical-stage biotechnology company developing investigational oral cannabidiol formulations for psychiatric disorders. Its NWPT-SM32300 programme uses a high-loading micellar softgel intended to deliver consistent oral doses. The company reports completion of a Phase 1 pharmacokinetic and…
Multimodal small molecule therapeutics for neurodegenerative disease
Elixa MediScience is a UK drug discovery company developing novel small molecule compounds designed to slow the progression and delay the onset of neurodegenerative diseases including Alzheimer's, Parkinson's and multiple sclerosis. The company's approach targets multiple pathophysiological mechanisms simultaneously,…
C. elegans whole-organism platform for preclinical drug and compound screening
Magnitude Biosciences Limited is a contract research organisation providing preclinical drug discovery and compound screening services using Caenorhabditis elegans as a whole-organism model. Its proprietary biophotonics platform enables automated, high-throughput, non-invasive monitoring of health and lifespan metrics…
Precision medicines targeting protein isoforms for neuromuscular disease
ISOgenix is a biotechnology company developing precision medicines that target disease-relevant protein isoforms for neuromuscular and neurological conditions. The company's approach focuses on identifying and modulating specific isoforms produced through alternative gene splicing and epigenetic regulation, aiming to…
AI-driven neural data platform for bioelectronic medicine
BIOS Health is a neural engineering company developing an AI-powered platform that reads and interprets peripheral nervous system signals in real time. Its technology links nerve activity to physiological conditions through the discovery of neural biomarkers, supporting the development of personalised neuromodulation…
Biomarker-guided therapeutics for psychosis-related cognitive impairment
Monument Therapeutics is a clinical-stage biopharmaceutical company developing stratified treatments for neuropsychiatric conditions. Its lead programme, MT1988, is being evaluated in people at clinical high risk of psychosis. A randomised, placebo-controlled Phase 1/2 study dosed its first participant in March 2026…
Mitochondrial sulfide-donor therapeutics for obesity and myopathies
MitoRx Therapeutics is a company developing first-in-class small molecule therapeutics that target mitochondrial sulfide signalling, a mechanism implicated in metabolic dysfunction and muscle disease. Its lead programme is an injectable mitochondria-targeted sulfide donor designed to achieve fat loss without lean mass…
Convection enhanced delivery consulting and devices for CNS therapeutics
Neurochase is a contract research and consulting organisation specialising in targeted drug delivery to the CNS using convection enhanced delivery. Working with pharmaceutical and biotechnology companies, it designs and optimises delivery strategies for gene therapies and other treatments directed at specific brain…